<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03325894</url>
  </required_header>
  <id_info>
    <org_study_id>SHP465-308</org_study_id>
    <nct_id>NCT03325894</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)</brief_title>
  <official_title>A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the long-term safety and tolerability of SHP465 at
      6.25 milligram (mg) in children aged 4 to 12 years diagnosed with
      Attention-Deficit/Hyperactivity Disorder (ADHD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Anticipated">June 21, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 21, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline up to Day 367 (Follow-up)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs are defined as AEs that start or deteriorate on or after the date of the first dose of investigational product and no later than 3 days following the last dose of investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline up to Day 367 (Follow-up)</time_frame>
    <description>Vital sign assessments include systolic and diastolic blood pressure, pulse, temperature, and respiratory rate. Any clinically significant deviations from baseline in vital signs that are deemed clinically significant in the opinion of the investigator are to be recorded as a TEAE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of Height</measure>
    <time_frame>Baseline up to Visit 16 (Day 360)</time_frame>
    <description>Height will be measured in inches or centimeters without shoes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of Weight</measure>
    <time_frame>Baseline up to Visit 16 (Day 360)</time_frame>
    <description>Weight will be measured in pounds or kilograms without shoes and with light clothing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Clinical Laboratory Results Reported as an Adverse Event</measure>
    <time_frame>Baseline up to Day 367 (Follow-up)</time_frame>
    <description>Clinical laboratory assessments include biochemistry and endocrinology, hematology and urinalysis. The investigator will assess out-of-range clinical laboratory values for clinical significance, to indicate whether or not the values are clinically significant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Reported as an Adverse Event</measure>
    <time_frame>Baseline up to Day 367 (Follow-up)</time_frame>
    <description>12-lead ECG will be performed using the central ECG provider's equipment and will be sent to the central ECG provider electronically. Any clinically significant change in ECG assessment will be reported as AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post Sleep Questionnaire (PSQ)</measure>
    <time_frame>Baseline up to Visit 16 (Day 360)</time_frame>
    <description>PSQ is a 7-item questionnaire typically used to assess sleep qualitywith pharmacologic treatment. The questionnaire collects data on average time to sleep, sleep latency, frequency of interrupted sleep, duration of interrupted sleep, total sleep time and sleep quality over the last week.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Children's Sleep Habits Questionnaire (CSHQ)</measure>
    <time_frame>Baseline up to Visit 16 (Day 360)</time_frame>
    <description>CSHQ is a tool designed to screen for the most common sleep problems in children and consists of 33 items for scoring and several extra items intended to provide administrators with other potentially useful information about respondents. The instrument evaluates the child's sleep based on behavior within 8 different subscales: bedtime resistance, sleep onset delay, sleep duration, sleep anxiety, night wakings, parasomnias, sleep disordered breathing, and daytime sleepiness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Columbia-suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Visit 3 (Day 7) up to Visit 16 (Day 360)</time_frame>
    <description>C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinician-administered Attention-deficit/Hyperactivity Disorder Rating Scale-5 (ADHDRS-5) Total Score</measure>
    <time_frame>Baseline, Visit 16 (Day 360)</time_frame>
    <description>ADHD-RS-5 consists of 18 items designed to reflect current symptomatology of ADHD based on diagnostic and statistical manual of mental disorders, fifth edition (DSM-5) criteria. Each item is scored on a 4-point scale ranging from 0 (reflecting no symptoms) to 3 (reflecting severe symptoms) with total scores ranging from 0-54. The 18 items may be grouped into 2 subscales: hyperactivity/impulsivity (9 items) and inattentiveness (9 items). Higher score represents more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Improvement (CGI-I)</measure>
    <time_frame>Visit 3 (Day 7) up to Visit 16 (Day 360)</time_frame>
    <description>CGI-I scale will be performed to rate the improvement of a participant's condition on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder (ADHD)</condition>
  <arm_group>
    <arm_group_label>SHP465</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A participants who have been rolled-over from antecedent SHP465 studies and Group B participants who will be newly enrolled into the study will receive SHP465 capsule 6.25 mg orally once daily for 360 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHP465</intervention_name>
    <description>SHP465 capsule will be administered in a dose of 6.25 mg orally once daily for 360 days.</description>
    <arm_group_label>SHP465</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is male or female aged 4-12 years inclusive at the time of consent.

          -  Participant's parent or legally authorized representative (LAR) must provide signature
             of informed consent, and there must be documentation of assent (as applicable) by the
             participant.

          -  Participant must meet Diagnostic and Statistical Manual of Mental Disorders, Fifth
             Edition (DSM-5) criteria for a primary diagnosis of ADHD (any subtype).

          -  Participant who is a female and of child-bearing potential must not be pregnant and
             agree to comply with any applicable contraceptive requirements..

          -  Participant has an ADHD-RS-5 Child, Home Version Total Score of greater than or equal
             to (&gt;=) 28 and Clinical Global Impression - Severity of Illness (CGI-S) score &gt;=4 at
             baseline (Visit 2). Participant is currently not on ADHD therapy, or is not completely
             satisfied with their current ADHD therapy.

        Exclusion Criteria:

          -  Participant is required or anticipated to take medications that have central nervous
             system effects or affect performance. Stable use of bronchodilator inhalers is not
             exclusionary.

          -  Participant has a concurrent chronic or acute illness, disability, or other condition
             that might confound the results of safety assessments conducted in the study or that
             might increase risk to the participant. - Participant has a documented allergy,
             hypersensitivity, or intolerance to amphetamine or to any excipients in the
             investigational product.

          -  Participant has failed to fully respond, based on investigator judgment, to an
             adequate course of amphetamine therapy.

          -  Participant has a known family history of sudden cardiac death or ventricular
             arrhythmia.

          -  Participant has a blood pressure measurement &gt;=95th percentile for age, sex, and
             height at screening (Visit 1) and/or baseline (Visit 2).

          -  Participant has a height less than or equal to (&lt;=) 5th percentile for age and sex at
             screening (Visit 1) or baseline (Visit 2).

          -  Participant has a weight &lt;=5th percentile for age and sex at screening (Visit 1) or
             baseline (Visit 2).

          -  Participant has a known history of symptomatic cardiovascular disease, structural
             cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, or other
             serious cardiac conditions placing them at increased vulnerability to the
             sympathomimetic effects of a stimulant drug.

          -  Participant has a history of seizures (other than infantile febrile seizures).

          -  Participant is taking any medication that is excluded per the protocol.

          -  Participant had any clinically significant ECG or clinical laboratory abnormalities at
             the screening (Visit 1) or baseline visit (Visit 2).

          -  Participant has current abnormal thyroid function, defined as abnormal
             thyroid-stimulating hormone and thyroxine at the screening or baseline visit.
             Treatment with a stable dose of thyroid medication for at least 3 months is permitted.

          -  Participant is currently considered a suicide risk in the opinion of the investigator,
             has previously made a suicide attempt, or has a prior history of or currently
             demonstrating suicidal ideation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Study Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harmonex Neuroscience Research</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelson M. Handal-Thome, MD</last_name>
      <phone>334-836-2000</phone>
    </contact>
    <investigator>
      <last_name>Nelson M. Handal-Thome, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PEWMD, PA, ARCSM, PLLC, PRP, Inc.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul E. Wylie, MD</last_name>
      <phone>501-553-9987</phone>
    </contact>
    <investigator>
      <last_name>Paul E. Wylie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Research Center</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Walsh</last_name>
      <phone>502-349-1569</phone>
    </contact>
    <investigator>
      <last_name>Patrick Walsh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riverside Medical Clinic</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael T. Saito</last_name>
      <phone>240-238-4917</phone>
    </contact>
    <investigator>
      <last_name>Michael T. Saito</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peninsula Research Associates - CRN</name>
      <address>
        <city>Rolling Hills</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence D. Sher</last_name>
      <phone>310-265-1623</phone>
    </contact>
    <investigator>
      <last_name>Lawrence D. Sher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Medical Associates</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard A. Gould</last_name>
      <phone>916-966-7452</phone>
    </contact>
    <investigator>
      <last_name>Richard A. Gould</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Care Research Center</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amol Malankar</last_name>
      <phone>305-994-7599</phone>
    </contact>
    <investigator>
      <last_name>Amol Malankar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Power MD Clinical Research Institute</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria A. Carballosa</last_name>
      <phone>305-443-3480</phone>
    </contact>
    <investigator>
      <last_name>Maria A. Carballosa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nandita Joshi Jones</last_name>
      <phone>+1 (904) 281-5757</phone>
    </contact>
    <investigator>
      <last_name>Nandita Joshi Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Acevedo Medical Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33142</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armando Acevedo</last_name>
      <phone>786-212-4187</phone>
    </contact>
    <investigator>
      <last_name>Armando Acevedo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175-0000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria I Delgado</last_name>
      <phone>786-703-5941</phone>
    </contact>
    <investigator>
      <last_name>Maria L Delgado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scientific Clinical Research, Inc.</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Segal</last_name>
    </contact>
    <contact_backup>
      <phone>+1 (305) 722-8444</phone>
    </contact_backup>
    <investigator>
      <last_name>Scott Segal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Bond Molpus</last_name>
      <phone>+1 (904) 281-5757</phone>
    </contact>
    <investigator>
      <last_name>Robert Bond Molput</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Associates of Orlando, Llc</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Elfaki</last_name>
      <phone>407-269-0322</phone>
    </contact>
    <investigator>
      <last_name>Ahmed Elfaki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GA Psychiatric Services, LLC.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30338-6520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suneel B. Katragadda, MD</last_name>
      <phone>770-458-0450</phone>
    </contact>
    <investigator>
      <last_name>Suneel B. Katragadda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Buford Family Practice</name>
      <address>
        <city>Buford</city>
        <state>Georgia</state>
        <zip>30519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Osowa</last_name>
      <phone>678-541-0588</phone>
    </contact>
    <investigator>
      <last_name>Alexander Osowa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>One Health Research Clinic, Inc.</name>
      <address>
        <city>Norcross</city>
        <state>Georgia</state>
        <zip>30093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hoyt Gazaway</last_name>
      <phone>678-585-4917</phone>
    </contact>
    <investigator>
      <last_name>Hoyt Gazaway</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute for Behavioral Medicine</name>
      <address>
        <city>Smyrna</city>
        <state>Georgia</state>
        <zip>30082</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashraf Attalla</last_name>
      <phone>770-319-8013</phone>
    </contact>
    <investigator>
      <last_name>Ashraf Attalla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research, Inc</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark A. Turner</last_name>
      <phone>+1 (208) 377-8653 x105</phone>
    </contact>
    <investigator>
      <last_name>Mark A. Turner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Conventions Psychiatry and Counseling</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandeep Gaonkar</last_name>
      <phone>630-416-8289</phone>
    </contact>
    <investigator>
      <last_name>Sandeep Gaonkar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pedia Research, LLC</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Christopher Sartore</last_name>
      <phone>812-604-0088</phone>
    </contact>
    <investigator>
      <last_name>J. Christopher Sartore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Psychiatric Associates</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Murphy</last_name>
      <phone>913-438-8221</phone>
    </contact>
    <investigator>
      <last_name>William Murphy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatric/Adult Research</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel J. Finn</last_name>
      <phone>502-349-1569</phone>
    </contact>
    <investigator>
      <last_name>Daniel J. Finn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qualmedica Research LLC, DBA Pedia Research</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carroll E. Howard</last_name>
      <phone>270-685-4589</phone>
    </contact>
    <investigator>
      <last_name>Carroll E. Howard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuroscientific Insights</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naveena Hemanth</last_name>
      <phone>301-468-1001</phone>
    </contact>
    <investigator>
      <last_name>Naveena Hemanth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurobehavioral Medicine Group</name>
      <address>
        <city>Bloomfield Hills</city>
        <state>Michigan</state>
        <zip>48302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard S Jackson</last_name>
      <phone>248-290-5400</phone>
    </contact>
    <investigator>
      <last_name>Richard S Jackson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Charles Psychiatric Associates</name>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <zip>63304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Mattingly</last_name>
      <phone>636-946-8032</phone>
    </contact>
    <investigator>
      <last_name>Gregory Mattingly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alivation Research, LLC.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526-9467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter James Duffy</last_name>
      <phone>+1 (402) 817-2235</phone>
    </contact>
    <investigator>
      <last_name>Walter James Duffy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Triangle Neuropsychiatry</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27707</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Chandler</last_name>
      <phone>919-401-6212</phone>
    </contact>
    <investigator>
      <last_name>Mark Chandler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio Pediatric Research Association</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie S. Shepard</last_name>
      <phone>937-236-5396</phone>
    </contact>
    <investigator>
      <last_name>Julie S. Shepard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Professional Psychiatric Services</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Aziz</last_name>
      <phone>523-229-7585</phone>
    </contact>
    <investigator>
      <last_name>Mohamed Aziz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Family Practice Center of Wadsworth, INC.</name>
      <address>
        <city>Wadsworth</city>
        <state>Ohio</state>
        <zip>44281-0000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew P. Finneran</last_name>
      <phone>330-334-6229</phone>
    </contact>
    <investigator>
      <last_name>Matthew P. Finneran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IPS Research Company</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise M. Thurman, MD</last_name>
      <phone>405-235-5585</phone>
    </contact>
    <investigator>
      <last_name>Louise M. Thurman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainbow Research, Inc.</name>
      <address>
        <city>Barnwell</city>
        <state>South Carolina</state>
        <zip>29812</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abraham H. Moskow</last_name>
      <phone>803-591-1033</phone>
    </contact>
    <investigator>
      <last_name>Abraham H. Moskow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Pediatric Associates</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Clifford</last_name>
      <phone>843-518-5642</phone>
    </contact>
    <investigator>
      <last_name>Robert Clifford</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Pediatric Associates</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Stripling</last_name>
      <phone>843-518-5642</phone>
    </contact>
    <investigator>
      <last_name>Stephen Stripling</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie K Arnold, MD</last_name>
      <phone>901-843-1045</phone>
    </contact>
    <investigator>
      <last_name>Valerie K Arnold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Access Clinical Trials, Inc.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James A. Fry</last_name>
      <phone>615-320-5340</phone>
    </contact>
    <investigator>
      <last_name>James A. Fry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>El Campo Clinical Trials</name>
      <address>
        <city>El Campo</city>
        <state>Texas</state>
        <zip>77437</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nilesh Patel</last_name>
      <phone>979-320-6173</phone>
    </contact>
    <investigator>
      <last_name>Nilesh Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Clinical Trials, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Katic</last_name>
      <phone>713-527-8448</phone>
    </contact>
    <investigator>
      <last_name>Alain Katic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Clinic</name>
      <address>
        <city>League City</city>
        <state>Texas</state>
        <zip>77573</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kokab A. Saeed</last_name>
      <phone>713-797-6000</phone>
    </contact>
    <investigator>
      <last_name>Kokab A. Saeed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-7822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Pliszka, MD</last_name>
      <phone>210-567-5484</phone>
    </contact>
    <investigator>
      <last_name>Steven Pliszka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Family Psychiatry of the Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marshall B. Lucas</last_name>
      <phone>281-367-1015</phone>
    </contact>
    <investigator>
      <last_name>Marshall B. Lucas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vishal Madaan</last_name>
      <phone>434-243-6366</phone>
    </contact>
    <investigator>
      <last_name>Vishal Madaan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA South Psychiatric &amp; Family Services</name>
      <address>
        <city>Petersburg</city>
        <state>Virginia</state>
        <zip>23805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thresa H. Simon, MD</last_name>
      <phone>804-861-0700</phone>
    </contact>
    <investigator>
      <last_name>Thresa H. Simon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arifulla Khan</last_name>
      <phone>425-453-0404</phone>
    </contact>
    <investigator>
      <last_name>Arifulla Khan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid-Columbia Research</name>
      <address>
        <city>Richland</city>
        <state>Washington</state>
        <zip>99352</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucien Thomas Megna</last_name>
      <phone>509-628-2331</phone>
    </contact>
    <investigator>
      <last_name>Lucien Thomas Megna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2017</study_first_submitted>
  <study_first_submitted_qc>October 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2017</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>SHP465</keyword>
  <keyword>Hyperactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

